This project explores pharmacokinetic and pharmacodynamic approaches to developing new treatments for drug dependence and reduction of HIV transmission risk behaviors, with a current focus on cocaine dependence. Almost all subjects are at high risk for contracting and spreading HIV infection. HIV transmission risk behaviors are assessed and HIV testing and risk reduction counseling are offered to all subjects. Pharmacokinetic approaches being studied include slow onset agonist substitution and enhancement of drug metabolism. Rate of onset of drug effect is considered an important influence on the reinforcing effects of drugs, but this has never been systematically studied in humans with stimulants. The influence of rate has treatment implications, in that drugs from the same pharmacologic class but with slower rate of onset may have therapeutic efficacy without themselves inducing addiction. One component of this project is systematically evaluating the influence of dose and infusion rate on the effects of IV cocaine. Preliminary findings suggest that at least some of cocaine's psychological and physiological effects are both dose- and rate- dependent, with some effects also exhibiting a dose by rate interaction. Enhancement of cocaine metabolism is being studied using butyrylcholinesterase (BChE),a major cocaine-metabolizing enzyme in humans. Increased BChE activity might reduce cocaine concentrations and thus cocaine's effects, with possible therapeutic benefits. In a collaborative study with the Preclinical Pharmacology Laboratory and the National Institute on Aging Gerontology Research Center, rats pretreated with BChE had a 50% reduction in motor activity response to an IP cocaine challenge compared to rats pretreated with saline. BChE itself had no effect on motor activity. BChE-treated rats had 400-fold increases in plasma BChE activity 24 hours after treatment, suggesting the possibility of persisting effects from a single enzyme administration. Further studies are evaluating the dose-response relationship and time course of this BChE effect.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000240-05
Application #
6161714
Study Section
Special Emphasis Panel (TB)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kanneganti, Praveen; Huestis, Marilyn A; Kolbrich, Erin A et al. (2008) Signal-averaged electrocardiogram in physically healthy, chronic 3,4-methylenedioxymethamphetamine (MDMA) users. Am J Drug Alcohol Abuse 34:712-20
Karila, Laurent; Gorelick, David; Weinstein, Aviv et al. (2008) New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 11:425-38
Soyka, Michael; Kranzler, Henry R; Berglund, Mats et al. (2008) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. World J Biol Psychiatry 9:6-23
Gorelick, David A; Kim, Yu Kyeong; Bencherif, Badreddine et al. (2008) Brain mu-opioid receptor binding: relationship to relapse to cocaine use after monitored abstinence. Psychopharmacology (Berl) 200:475-86
Huestis, Marilyn A; Boyd, Susan J; Heishman, Stephen J et al. (2007) Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 194:505-15
Gorelick, David A (2007) Regarding ""Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system"". Biol Psychiatry 62:702;author reply 702
Gorelick, David A (2006) Counseling plus buprenorphine-naloxone for opioid dependence. N Engl J Med 355:1736; author reply 1736-7
Gorelick, David A; Heishman, Stephen J; Preston, Kenzie L et al. (2006) The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J 151:754.e1-754.e5
Nelson, Richard A; Boyd, Susan J; Ziegelstein, Roy C et al. (2006) Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend 82:19-24
Gorelick, David A; Wilkins, Jeffery N (2006) Bromocriptine treatment for cocaine addiction: association with plasma prolactin levels. Drug Alcohol Depend 81:189-95

Showing the most recent 10 out of 19 publications